Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7395646 | 0.89 | GPR119 (0.51) | GPR119SCN9A | |
| SCHEMBL345454 | 0.89 | GPR119 (0.51) | GPR119SCN9A | |
| SCHEMBL3124615 | 0.89 | GPR119 (0.51) | GPR119SCN9A | |
| SCHEMBL310750 | 0.87 | GPR119 (0.57) | GPR119SCN9A | |
| SCHEMBL1710891 | 0.87 | MEN1 (0.47) | GPR119SCN9A | |
| SCHEMBL30922520 | 0.87 | MEN1 (0.47) | GPR119SCN9A | |
| SCHEMBL26132616 | 0.86 | NR1H2 (0.43) | NR1H2GPR119 | |
| SCHEMBL445759 | 0.85 | NR1H2 (0.51) | NR1H2GPR119NAMPTSCN9A | |
| SCHEMBL17311035 | 0.83 | NR1H2 (0.42) | NR1H2GPR119 | |
| SCHEMBL16963661 | 0.83 | NR1H2 (0.42) | NR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4347579-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2024-04-10 | — | — | EP | disclosed |
| EP-4236928-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1Cbio, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| EP-4065578-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114901659-A | Fused pyrimidinone compounds as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2022-08-12 | — | — | CN | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | NR1H2 1082/4885GPR119 2936/4885NAMPT 589/4885 |
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MCL1, MDM2, XIAP | NR1H2 3137/4885GPR119 4565/4885NAMPT 3708/4885 |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | NR1H2 1082/4885GPR119 2936/4885NAMPT 589/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | NR1H2 4690/4885GPR119 2487/4885NAMPT 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.